Omid Farokhzad

Omid Farokhzad is an Advisor at Tarveda Therapeutics and a renowned authority in the field of nanomedicine. Omid has previously served as Director of the Center for Nanomedicine at Brigham and Women's Hospital, where they were also a founding member of the Lab of Nanomedicine. At Harvard Medical School, Farokhzad was an Instructor in the Department of Surgery from 2004-2006.

Farokhzad's research focuses on the development of targeted therapeutics and the use of nanoparticles for drug delivery. Omid has been instrumental in the development of several groundbreaking nanomedicines, including BIND-014, the first clinical-stage nanoparticle to demonstrate targeting and uptake by cancer cells. Omid is also the co-founder of several companies in the nanomedicine space, including Seer, XIRA Connect, and PrognomiQ Inc.

Farokhzad has received numerous awards and honors for their work in nanomedicine, including the 2016 American Association for Cancer Research (AACR) Team Science Award, the 2018 Lurie Prize in Biomedical Sciences, and election to the National Academy of Medicine in 2020.

Omid Farokhzad graduated from the Harvard-MIT Division of Health Sciences and Technology with a post-doctoral fellowship in nanomedicine and biomaterials. Omid then completed their residency in anesthesiology and fellowship in pain medicine at Brigham and Women's Hospital, Harvard Medical School. After obtaining their M.B.A. from the MIT Sloan School of Management, they returned to Boston University School of Medicine to obtain their M.D., M.A.